Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Hiroki KUMAGAI"'
Autor:
Fumito Hamada, Hikaru Hori, Hitoshi Iida, Hiroyuki Yokoyama, Hiroko Sugawara, Akito Hatanaka, Leo Gotoh, Muneaki Ogata, Hiroki Kumagai, Rika Yano, Yuko Tomiyama, Tetsuya Yoshida, Yoshimi Yamaguchi, Ryo Asada, Masato Masuda, Yuta Okamoto, Hiroaki Kawasaki
Publikováno v:
Metabolites, Vol 13, Iss 9, p 981 (2023)
Treatment of bipolar disorder is prone to prolongation despite various treatments, including medication. The efficacy of exercise treatment (i.e., interventions involving physical exercise and sports intervention) for major depressive disorders has b
Externí odkaz:
https://doaj.org/article/dbfe5c40b2504291b3dc8de07d9d3d1a
Autor:
Naoto Kubota, Tetsuya Kubota, Eiji Kajiwara, Tomokatsu Iwamura, Hiroki Kumagai, Taku Watanabe, Mariko Inoue, Iseki Takamoto, Takayoshi Sasako, Katsuyoshi Kumagai, Motoyuki Kohjima, Makoto Nakamuta, Masao Moroi, Kaoru Sugi, Tetsuo Noda, Yasuo Terauchi, Kohjiro Ueki, Takashi Kadowaki
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-16 (2016)
Type 2 diabetes and obesity are associated with increased hepatic gluconeogenesis and lipogenesis, known as selective insulin resistance. Here Kubota et al. explain selective insulin resistance in the liver with the zonal distribution and selective i
Externí odkaz:
https://doaj.org/article/67f78d5db20e41daba34da37bdfe2d92
Autor:
Takayasu Ohtake, Shoichi Itaba, Amankeldi A Salybekov, Yin Sheng, Tsutomu Sato, Mitsuru Yanai, Makoto Imagawa, Shigeo Fujii, Hiroki Kumagai, Masamitsu Harata, Takayuki Asahara, Shuzo Kobayashi
Publikováno v:
World Journal of Stem Cells. 15:268-280
Publikováno v:
CHROMATOGRAPHY. 44:33-37
Autor:
Hiroki Kumagai, Hirokazu Sawada
Publikováno v:
BUNSEKI KAGAKU. 69:135-139
Autor:
Katsuyoshi Kumagai, Naoto Kubota, Makoto Nakamuta, Iseki Takamoto, Taku Watanabe, Motoyuki Kohjima, Takayoshi Sasako, Kohjiro Ueki, Kaoru Sugi, Mariko Inoue, Tetsuo Noda, Yasuo Terauchi, Hiroki Kumagai, Eiji Kajiwara, Tomokatsu Iwamura, Tetsuya Kubota, Takashi Kadowaki, Masao Moroi
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-16 (2016)
Nature Communications
Nature Communications
Hepatic insulin signalling involves insulin receptor substrates (Irs) 1/2, and is normally associated with the inhibition of gluconeogenesis and activation of lipogenesis. In diabetes and obesity, insulin no longer suppresses hepatic gluconeogenesis,
Autor:
Masato Akahira, Tadamasa Arai, Eiki Takahashi, Hiroki Kumagai, Kazumi Nishimura, Mayumi Nakajima, Yu Omori, Tomohiko Suzuki, Ryoji Hayashi
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:4603-4606
We describe the discovery of phenoxymethylbenzamide derivatives as a novel class of glycine transporter type-2 (GlyT-2) inhibitors. We found hit compound 1 (human GlyT-2, IC50 = 4040 nM) in our library and converted its 1-(1-(naphthalen-2-ylmethyl)pi
Autor:
Yumiko Sekiya, Satoshi Sakami, Hiroki Kumagai, Takehiro Takahashi, Koji Kawai, Aiko Nitta, Seiji Okazaki, Tomokatsu Iwamura, Mikiya Sato, Mai Yagi, Junko Nakaki, Mie Kainoh
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 351:181-189
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is considered a potential therapeutic target in the treatment of type 2 diabetes mellitus. In this study, we investigated the pharmacological properties of HIS-388 (N-[(1R,2s,3S,5s,7s)-5-hydroxyada
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 25:3921-3923
A series of novel indolylpiperidine derivatives were synthesized, and their pharmacological profiles were assessed at rat α1A and α1B adrenoceptors through in vitro binding studies. Compound 12 (2-(3-(4-(6-fluoro-1H-indol-3-yl)piperidin-1-yl)propyl
Autor:
Hiroki Kumagai, Takehiro Takahashi, Kaoru Sugi, Naoto Kubota, Kaito Iwayama, Tetsuya Kubota, Tomoko Kawai, Takashi Kadowaki, Masao Moroi, Mariko Inoue
Publikováno v:
Diabetology International. 4:226-232
Pioglitazone (PIO) is widely used as an insulin-sensitizing agent in the treatment of type 2 diabetes, but it also causes an increase in body weight in a dose-dependent manner. Beraprost sodium (BPS), a stable prostaglandin I2 analog, is used clinica